<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We previously reported that <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> lipase mass levels in preheparin serum (preheparin LPL mass) was significantly lower in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> compared to healthy subjects and that low preheparin LPL mass may be a high-risk factor of <z:hpo ids='HP_0004929'>coronary atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to clarify the effects of <z:chebi fb="0" ids="6801">metformin</z:chebi> on serum <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> lipase mass levels (preheparin LPL mass), adiponectin and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-eight patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (HbAlc&gt;7.0%), who were already receiving <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> agents, took <z:chebi fb="0" ids="6801">metformin</z:chebi> 500 mg orally twice daily for 3 months </plain></SENT>
<SENT sid="3" pm="."><plain>Fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> (FBG), immunoreactive insulin (basal IRI) and HbAlc decreased significantly after <z:chebi fb="0" ids="6801">metformin</z:chebi> treatment </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="15" ids="39026">LDL</z:chebi>-Rm ratio decreased significantly (from 0.3521+/-0.046 to 0.3339+/-0.030, P&lt;0.05) and preheparin LPL mass increased significantly (from 42.5+/-3.2 to 50.6+/-3.5 ng/ml, P&lt;0.0005), but adiponectin was unchanged </plain></SENT>
<SENT sid="5" pm="."><plain>The correlation of a change of <z:chebi fb="15" ids="39026">LDL</z:chebi>-Rm ratio and a change of preheparin LPL mass showed a negative correlation tendency </plain></SENT>
<SENT sid="6" pm="."><plain>The changes in <z:chebi fb="15" ids="39026">LDL</z:chebi>-Rm ratio and preheparin LPL mass were independent of the hypoglycemic effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>These results suggest that <z:chebi fb="0" ids="6801">metformin</z:chebi> may increase LPL production, thereby increasing <z:chebi fb="15" ids="39026">LDL</z:chebi> particle size </plain></SENT>
<SENT sid="8" pm="."><plain>These effects might be independent of the hypoglycemic effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
</text></document>